The Caledonian-Record

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use ...

The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in ...

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights

Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...

Synteca Bio Redesigns Blockbuster Antibodies With AI, Demonstrates Potential for High-Solubility Biobetter Development

SYNTECA BIO, an artificial intelligence (AI)-based drug development company, has secured a biobetter candidate with improved solubility over conventio ...

Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?

Keytruda now holds more than 40 FDA-approved indications spanning 19 tumor types. The drug has played an instrumental role in ...
Solicitors Journal

Patents Court rejects MSD's bid for wider Mayne Pharma disclosure in Halozyme hyaluronidase dispute

The Patents Court has dismissed an application by Merck Sharp & Dohme (UK) Limited seeking further disclosure of experimental ...